|
Palo Alto, CA, August 4, 2005 — Telik, Inc. (Nasdaq: TELK) reported a net loss of $21.0 million, or $0.40 per share, for the second quarter ended June 30, 2005, compared with a net loss of $17.7 million, or $0.41 per share, for the comparable period in 2004. For the quarter ended June 30, 2005, total operating expenses increased to $22.8 million, from $18.3 million for the same quarter in 2004.
For the six months ended June 30, 2005, Telik reported a net loss of $41.4 million, or $0.82 per share, compared with a net loss of $33.0 million, or $0.76 per share, for the six months ended June 30, 2004. Total operating expenses increased to $44.6 million for the six months ended June 30, 2005 from $34.2 million in the first six months of 2004.
The increase in total operating expenses in the second quarter and six months ended June 30, 2005 as compared to the same periods in 2004 was primarily due to expanded clinical development of TELCYTA™ (TLK286), including three ongoing Phase 3 registration trials (ASSIST-1, ASSIST-2, and ASSIST-3) in ovarian and non-small cell lung cancer and the ongoing Phase 2 clinical development of TELINTRA™ (TLK199).
At June 30, 2005, Telik had cash and equivalents of $238.2 million, compared with $138.6 million at December 31, 2004.
Conference Call and Webcast
Telik will host its quarterly conference call today at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). The conference call will be accessible via Telik’s website at www.telik.com or by telephone at 888-423-3280 or 612-332-0530. An archive of the conference call will be available on the Telik website from approximately 8:00 p.m. Eastern time on August 4 through August 11, 2005, or by telephone at 800-475-6701 or 320-365-3844, access code 791463.
About Telik
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA (TLK286), a tumor-activated small molecule product candidate that is in three Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
Click here for Second Quarter 2005 Statements of Operations
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2005 Press Releases2004
Press Releases
2003
Press ReleasesEvents |
